These data suggest that selection of EphA2-positive cancer patients for treatment with EphA2-ILs-DTXp may be accomplished by measurement of the EphA2 using IHC in the primary surgical resections rather than in fresh biopsies. This evidence concerns the gene EPHA2 and cancer.